Cite
HARVARD Citation
Segelov, E. et al. (n.d.). 32LBA The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation – analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. European journal of cancer. pp. S726-. [Online].